More than in any previous year, 2023 has seen a rising number of "space tourists". Besides the effects of zero gravitiy, does space impact our immune system?
The annual international congress took place as a hybrid event in Copenhaguen and online during 14-16 October with over 11,000 participants.
Various chronic allergic diseases still need treatment options. Novel agents are under investigation or were approved, diversifying options and increasing efficacy.
With many studies on novel compounds underway, more options for topical treatments of atopic dermatitis (AD) will soon be within reach.
Oral onychomycosis treatment is still the gold standard, but topical armamentarium use is rising, although use of many novel oral and topical agents is off-label.
In 6 dosage types of remibrutinib, chronic spontaneous urticaria patients benefitted in symptoms such as itch, sleep, and activity, already after 2 weeks.
IL-36 receptor antibody spesolimab improved erythema, pustulation, and scaling/crusting of skin lesions in generalised pustular psoriasis (GPP).
A post-hoc analysis of the EASE trial revealed that birch extract gel significantly lowered changes, and alleviated the burden of this disease.
A study including 7,144 patients revealed that therapy with IL-23 blockers was associated with lower risk of inflammatory or psoriasis arthritis.
Dr Mendes Bastos addressed the heterogeneity of atopic dermatitis patients, causes, and therapy options, and the ongoing research to address them.
Clinically meaningful improvements in Eczema Area and Severity Index (EASI) were observed with amlitelimab treatment for atopic dermatitis.
Excluding severe AA, 83–93% of participants in the ALLEGRO-LT trial reached an 80% re-growth of scalp hair or more after 15 months of treatment.
Skin tape stripping is an effective, non-invasive way to detect biomarkers associated with early disease in hidradenitis suppurativa.
A cohort study from the BADBIR registry revealed that IL-23p19 inhibitors are associated with the highest drug survival regarding effectiveness and safety.
In a small study, treating different severe hand eczemas with dupilumab led to favourable results. At week 16, 19 of 20 participants reached HECSI75.
Continuing povorcitinib treatment after a 6-month double-blind phase led to additional repigmentation for many participants of a vitiligo phase 2b trial.
Long-term conventional systemic therapies lead to higher drug-related adverse events and treatment discontinuation rates compared with biologics.
Extended treatment with ruxolitinib cream resulted in substantial response rates in patients who had demonstrated no or little response after 6 months.
The agent led to remarkable clinical responses for hidradenitis suppurative in the phase 2 MIRA trial. It was relatively well tolerated without new safety signals.
Upadacitinib therapy led to robust clinical efficacy and itch relief in adolescents and adults with moderate-to-severe atopic dermatitis in 3 ongoing phase 3 trials.